Precise, reproducible, and regulatory-ready: CE-based methods are redefining how scientists characterize therapeutic mAbs and ADCs across the biotherapeutic development pipeline.
Asahi Kasei Life Science has acquired the license rights for a
novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.
Acquisition strengthens US peptide manufacturing capabilities and broadens global expertise in complex peptide APIs
Hongene Biotech delivers end-to-end CDMO services for SiranBio's dual-target siRNA hepatitis B candidate, from raw materials through cGMP manufacturing, highlighting its capabilities in oligonucleotide therapeutics.
Bristol Myers Squibb licenses Lonza's SYNtecan linker-payload platform to advance an undisclosed ADC target, with Lonza eligible for upfront payments, milestones and royalties on resulting products.
Piramal Pharma Solutions opens a new payload-linker suite in Michigan as part of a $90 million US investment plan, bolstering its ADC manufacturing capabilities across sites in Riverview and Lexington.
All closing conditions satisfied for the acquisition of three small molecule sites in the US and Australia; closing to occur as of May 1, 2026. Adds highly demanded US-based manufacturing capacity to Siegfried's network.
In this CHEManager Leaders & Motivators interview, Frank Romanski, Lonza Capsugel, reflects on how strategy becomes execution and what resilience demands from teams,
The investment, its largest since its inception, demonstrates continued progress against AbbVie's $100 billion commitment to US R&D and capital investments, including manufacturing, over the next decade.
Evonik is expanding its biotechnological production capacities at the Fermas site in Slovenská Ľupča with an investment of around €80 million
Byphar is Brenntag's new biopharma-focused brand designed to bring quality, efficiency and flexibility to every stage of biopharmaceutical manufacturing.
Acquisition includes industry-leading ADC platform, its clinically-validated tubutecan linker-payload technology, and next-generation platform to expand Gilead’s ADC capabilities.
Ofichem has unified its six brands under the single Ofichem name, creating a fully integrated, family-owned CDMO and pharmaceutical supplier.
On Demand | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.
The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.
As discovery accelerates and throughput rises, digital transformation is becoming essential for chemistry labs. AI, robotics, and data growth must be orchestrated to boost productivity—rather than overwhelm the lab.
AI and evolving regulations set to transform biopharma operations in drug development and quality.
At CPhI Frankfurt, Christene Smith of CHEManager International interviews Axplora CCO Arul Ramadurai on navigating industry uncertainty and building strategic partnerships.
Sandoz has announced the creation of a new biosimilar development, manufacturing and supply unit.
Symbiosis Pharmaceutical Services has appointed experienced commercial leader Joanne Anderson as Chief Commercial Officer to drive global growth following recent capacity investments and expansion plans.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
Forma Life Sciences launches as US-based contract development and manufacturing organization (CDMO) for oral solid dosage development and commercial manufacturing in Irvine, California.
As CROs and CDMOs expand their role in biopharma development and manufacturing, fast, accurate bioanalytic technologies remain critical to biotherapeutic affordability.
DFE Pharma announces the launch of its continuous manufacturing (CM) platform. It is designed to support pharmaceutical companies in the development, optimization, and lifecycle management of CM processes.
AsymBio, a subsidiary of Asymchem Group, has established integrated technology platforms including cell line development, upstream/downstream processing, conjugation toolbox, and analytics.
Fujifilm Biotechnologies expanded manufacturing and process development presence in the North East of England to support vital biomanufacturing of innovative medicines and vaccines in the United Kingdom.
Veit Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology as well as automation in production from April 1, 2026.
Sanofi has completed its acquisition of Dynavax, adding its adult vaccines and pipeline candidates to strengthen Sanofi’s presence in adult immunization.
WuXi Biologics partners with Sinorda on bispecific antibodies for autoimmune diseases and HanchorBio on fusion proteins for oncology and immunology.
This infographic hopes to provide scientists with a comprehensive overview of fluorescence imaging strategies for extracellular vesicle research.
How CDMOs are navigating uncertainty, forging partnerships, and embracing flexibility.
Fourth major US manufacturing investment announced this year, advancing AstraZeneca’s historic $50 billion commitment to medicines manufacturing and R&D.
New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced therapies from early research to clinical readiness.
AGC Biologics has partnered with Rarity PBC to provide development and GMP manufacturing of a gene therapy aimed at treating a rare, life-threatening immune disorder.
Novartis plans to establish a flagship manufacturing hub in North Carolina by 2027-2028 as part of a $23 billion investment in US infrastructure.
